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Development of the haemochorial placenta involves the invasion of extravillous trophoblast cells 
into the uterine wall and subsequent remodelling of the uteroplacental vessels. Although 
myometrial invasion by cytotrophoblast cells is a crucial step in early placentation, the 
mechanisms underlying this pivotal process, essential for pregnancy maintenance, are 
incompletely understood. We hypothesized that fetal cytotrophoblast invasion of the uterus 
requires the synergistic modulation by both cell adhesion and angiogenesis, two processes which 
are essential for haemochorial placentation. In this regard, we have demonstrated for the first time 
presence of a potent angiogenic factor, angiogenin in placenta throughout gestation (Rajashekhar 
et al., 2002). Our finding of the enhanced expression of this pivotal angiogenic factor at term 
compared in with first trimester (FT) chorionic villi is in accordance with that of the exponential 
increase in fetal growth during the third trimester when a dramatic rise in the growth of the 
placental bed occurs (Ahmed and Perkins, 2000). Further to this observation, investigation of the 
placenta from patients with intrauterine growth retardation (IUGR) revealed over-expression and 
secretion of this pivotal angiogenic molecule. The enhanced angiogenin production which could 
be attributed to the ability to circumvent the poor oxygenation resulting from defective 
fetoplacental blood flow by autoregulation could serve as positive feed back control to induce 
angiogenesis (Rajashekhar et al., 2003). To understand the molecular mechanism of this over-
expression and its association with hypoxia, term placental explants in culture when subjected to 
hypoxia showed increased expression of angiogenin thus providing a direct evidence for 
compensatory rise for this angiogenic factor in conditions associated with deficient oxygen 
supply. Moreover, the extracellular matrix (ECM) proteins in vitro amplified the production of 
angiogenin release from trophoblasts in culture as well as its mRNA transcripts, thus providing 
evidence that the interactions occur among cell adhesion molecules and angiogenic growth 
factors. In addition, angiogenin production was reduced by compounds that interfere with integrin 
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function, such as anti-integrin antibodies, suggesting an important role of ECM binding in the 
regulation of angiogenin release. This synergy between cell adhesion molecules and angiogenic 
growth factors could have a key role in cellular invasion and migration, processes that are 
essential for angiogenesis and subsequent placental growth. 
  
Pre-eclampsia (PE) and IUGR have been attributed to a failure of trophoblast invasion 
which leads to underperfusion of the uteroplacental bed. The interaction between maternal 
leukocytes and decidual cells with the invading trophoblast is thought to be established by cell 
adhesion molecules. In this context, the vascular cell adhesion molecule-1 (VCAM-1), which is a 
member of the immunoglobulin gene superfamily has been reported to play a proangiogenic role 
in inducing chemotaxis of human endothelial cells in vitro that is essential for angiogenesis and 
subsequent placental development. We hypothesized that a failure of normal placentation with 
dysregulation of VCAM-1, the marker of endothelial activation might explain the aetiology of 
late onset IUGR (>32 weeks of gestation). In this study therefore, using placental explant cultures 
and RT-PCR, we determined the expression and secretion profiles of this pivotal cell adhesion 
molecule during the course of gestation and compared it with pregnancies complicated by IUGR. 
A decrease in mRNA expression and secretion of VCAM-1 in the term chorionic villi over the FT 
placenta occurred which was further decreased in IUGR placenta, suggesting that the diminished 
levels of VCAM-1 might contribute to the pathological state.  
 
In addition to the key regulatory agents discussed above, expression profiles of other 
growth factors including placental growth factor, epidermal growth factor as well as cell adhesion 
molecules like intercellular adhesion molecules (ICAM-1, -2, -3), P-selectin and VE-cadherin in 
normal and pathological pregnancies were studied. The results of this study indicated a higher 
mRNA expression of ICAM-2 and P-selectin at term than FT samples, and their decrease in PE 
 xxii
and IUGR. PlGF showed higher levels at FT than term placenta, the concentrations of which were 
further decreased in PE and IUGR. In conclusion, the pathological pregnancy could be attributed 
to a defective expression and secretion of cell adhesion molecules and growth factors. 
 
In a bid to understand the hitherto undescribed molecular mechanism(s) for the survival 
and proliferation of malignant trophoblasts in the gravid uterus (Gestational Trophoblastic 
Disease, GTD), we have documented the co-expression of Fas and FasL in choriocarcinoma, and 
hypothesized a role for these malignant trophoblasts in immune-privilege. Using the well-
characterized choriocarcinoma cell line, BeWo and the uterine choriocarcinoma cell line, NJG, 
we provided evidence that the Fas receptors are down regulated and show resistance to Fas-
mediated apoptosis. This could be attributed to the presence of a short-lived endogenous inhibitor 
like cFLIP as demonstrated by the RT-PCR method. In addition, co-culture of these 
choriocarcinoma cells, which express functional FasL, was noted to induce apoptosis in Fas-
sensitive lymphocytic Jurkat cells, suggesting that these tumour cells possess the capacity to 
evade immune attack thereby imparting immune-privilege. In conclusion, the data suggest that 
choriocarcinoma cells could evade immune attack by downregulating the Fas receptor and killing 
the lymphocytes through expression of FasL. Investigations on such molecular mechanisms might 
provide greater insight into the mechanisms associated with tumour survival and offer possible 
therapeutic approaches in the treatment of GTD.  
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